ADMIRAL

(redirected from Admiral's)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to Admiral's: Admiral's Men
Abciximab before Direct Angioplasty & Stenting in Myocardial Infarction Regarding Acute & Long-Term Follow-Up. A trial assessing clinical benefit of abciximab + primary stenting for acute MI
Primary endpoint Composite—death, reinfarction, urgent revascularization of target vessel at 30 days
Conclusion Early abciximab in acute MI improves coronary patency before stenting, stenting success, coronary patency at 6 months, recovery of left ventricular function, outcomes

ADMIRAL

Cardiology A clinical trial–Abciximab before Direct Angioplasty & stenting in Myocardial Infarction Regarding Acute and Long-term followup. See Abciximab, Angioplasty, Myocardial infarction, Stenting.
Mentioned in ?
References in periodicals archive ?
Mr Engelhardt will remain with Admiral in a part-time executive role, when he is succeeded by Admiral's current chief operating officer David Stevens as chief executive on May 12.
Admiral's ENVIROTERRA(tm) product line is the first high performance completely biodegradable non-acid and non-corrosive, all-purpose industrial liquid cleaners.
Admiral's products ENVIROTERRA and TEMPEST are the first completely biodegradable non-acid and non-corrosive, all-purpose industrial liquid cleaners which are Agriculture Canada approved for use in food and beverage processing facilities.
Bayer also stated, "Given our national reach, our acquisitions, Admiral's long-standing sales growth from existing products, and considering the acceptance we are seeing across a range of new products, it is management's view that the increases in sales and earnings we have seen in the first quarter of our new fiscal year are a window on the future for Admiral.
This manufacturing now moves to Admiral's Toronto facility, contributing greatly to the efficiencies within our plant.
Bayer, Chairman and CEO of Admiral: "This acquisition dramatically broadens Admiral's scope, taking us into a proven consumer product category.
Sanchez will turn over CEO duties to Admiral Zlatoper and will look to the Admiral's much-admired management abilities and international market knowledge to help Sanchez implement a global expansion plan and work to meet market demand for its PROFILE(R)/Anyware software.
This Report covered Admiral's first year as a public company pursuant to its IPO in April of 1996.
Bayer stated that, with the integration of the two companies, Admiral's sales will increase to $5.
Bayer stated that this acquisition will increase Admiral's sales by approximately 15 percent and profitability by approximately 50 percent.